NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Thursday 28 April 2011

Sales fell 14% at DSM's pharma business reflecting a drop in volumes in DSM Pharmaceutical Products

DSM

Record sales for SAFC

Sales for Sigma-Aldrich's SAFC division grew by 16% to $180m in Q1 2011 compared to 2010. Kirk Richter, Sigma-Aldrich's Interim Chief Financial Officer, Vice President and Treasurer, said this growth at SAFC was partially due to continued strong demand by biopharma customers as sales of biological drugs continue to expand and also to strong demand for materials and precursors for semi-conductor and LED applications. Rakesh Sachdev, Chief Executive Officer, President and Director, said SAFC has a record level of booked orders for future delivery.
Seeking Alpha

Thursday 21 April 2011

TG United will provide commercial-scale manufacturing for Adeona Pharmaceutical's reaZin

Adeona Pharma

Hebei Aoxing API Pharmaceutical Company has adopted advanced process technology from Macfarlan Smith to manufacture naloxone hydrochloride API

In-pharma Technologist

Strong Q1 for Albemarle

Net sales for Albemarle's fine chemicals business rose 30% to $177.3m in Q1 2011 and income rose 151% to $29.5m. The company said the improvement was due primarily to higher volumes and favourable pricing.
Business Week

Monday 18 April 2011

Bakhu to acquire Phoenix site

Bakhu Pharma has acquired the IP assets of Phoenix Chemicals and is negotiating to purchase the Annan, Scotland, site from the administrators, RSM Tenon. The acquisition is expected to be completed in the next few weeks. Bakhu Pharma was incorporated on 31 March.
BBC

Wednesday 13 April 2011

Lonza reported a good Q1 2010 but warned that the strong Swiss franc and high raw material prices would dent its H1 performance

Lonza

Dr Reddy's opens Chirotech expansion

Dr Reddy's has inaugurated the new headquarters for its Cambridge, UK, subsidiary Chirotech and plans to invest further in the site. Chirotech provides development services in the areas of chiral technologies, particularly chemocatalysis and biocatalysis.
Financial Times

Monday 4 April 2011

Kevin Cook has been appointed as Managing Director of Aesica's API business unit

Aesica

Following completion of the acquisition, Fujifilm has renamed the Merck Biomanufacturing Network as Fujifilm Diosynth Biotechnologies

Contract Pharma

BASF increases prices

BASF is increasing the prices of its pharmaceutical excipients and APIs by at least 10% depending on the product group. The company said it is raising prices as a result of a rise in costs for raw materials, energy and labour.
BASF